Trial Profile

A DOSE-BLINDED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF UCB0599 IN STUDY PARTICIPANTS WITH PARKINSON'S DISEASE

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 27 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Minzasolmin (Primary)
Indications Parkinson's disease
Focus Therapeutic Use
Sponsors UCB Biopharma

Most Recent Events

27 Apr 2025 Last checked against ClinicalTrials.gov record.
15 Apr 2025 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: Based on available data, the decision was made to stop development of UCB0599/minzasolmin as treatment of Parkinson's Disease.
18 Feb 2025 Planned End Date changed from 8 Oct 2029 to 21 Apr 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com